Centre National De La Recherche Scientifique

UniversitÉ De Poitiers

Universitè{grave Over ( )} De Poitiers

Manros Therapeutics

Frédéric Becq

Laurent Meijer

Caroline Norez

Conrad Kunick

Yvette Mettey

Jean Michel Vierfond

Christian Rogier

Michel Joffre

Cécile Marivingt-Mounir

Renaud Robert

Laurence Pignoux

The invention relates to the use of purine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells, said derivatives being of formula (I): where R2, R6 and R9, independently=halogen, a R&#x2014;NH&#x2014;, R&#x2014;NH&#x2014;NH&#x2014;, NH&#x2014;R'&#x2014;NH or R&#x2014;NH&#x2014;R&#x2032;&#x2014;NH&#x2014; group, where R=straight or branched chain saturated or unsaturated alkyl, aryl, cycloalkyl, or heterocyclyl group, R&#x2032;=straight or branched chain, saturated or unsaturated alkylene, arylene or cycloalkylene, R and R&#x2032; each include 1 to 8 carbon atoms optionally substituted with one or more &#x2014;OH, halogen, amino or alkyl groups, R2 furthermore may be a heterocycle optionally with a straight or branched chain saturated or unsaturated alkyl, aryl or cycloaryl or a heterocycle optionally substituted by one or more &#x2014;OH, halogen, amino or alkyl groups, R9 furthermore may be a straight or branched chain saturated or unsaturated alkyl, aryl or cycloalkyl and R2 and R9 furthermore may be hydrogen with the exception of 2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine.

Use of purine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells

A treatment of cystic fibrosis by administration of a pharmaceutically acceptable amount of the glucosidase inhibitor NB-DMJ (N-butyldeoxy-mannojirimycin).

Use of glucosidase inhibitors for therapy of mucovisidosis

A method provides for the use of glycosidase inhibitors selected from compounds of general formula (1), wherein Rrepresents a CHgroup, or CHOH, Rrepresents H or an alkyl group having 1-5 carbon atoms, or Rand Rtogether form a group having formula (II), with carbon in position (a) and nitrogen of formula (I) mentioned above, for the preparation of a medicament used to treat mucovisidosis. A corresponding product is also described.

The invention relates to the use of benzo[c]quinolizinium derivatives for treating diseases that are linked to smooth muscle cell constriction, such as hypertension and asthma.

Use of benzo[c]quinolizinium derivatives for the treatment of diseases that are linked to smooth muscle cell constriction

The invention relates to paullone derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells, said derivatives being of general formula (1): wherein X&#x2550;C&#x2550;O, C&#x2014;S&#x2014;CH, C&#x2014;S, &#x2014;C&#x2014;NHOH, Z&#x2014;C or N, Y&#x2014; with the adjacent ring, a phenyl or thienyl group, the ring(s) of said derivatives being optionally substituted with one or more halogen atoms, hydroxy, alkylenehydroxy, alkynealkylenehydroxy, alkynehydroxycyclohexyl, alkyl, alkoxy, alkylenealkoxy, or alkylenecyano groups where the alkylene group is either saturated or unsaturated, the groups having a straight or branched chain with C1 to C18, said chain being optionally substituted with one or more hydroxy or amino groups, or one or more trifluoromethyl, &#x2014;COM, &#x2014;COOM, or &#x2014;CHCOOM groups (where M=H, C1 to C18 straight or branched chain alkyl, optionally substituted with one or more hydroxy and/or amino groups) nitroso, or cyano, R&#x2550;H, or C1 to C5 alkyl and R&#x2550;H, or &#x2014;C&#x2014;CO&#x2014;(CH)and the physiologically-acceptable salts and derivatives thereof.

Use of paullone derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells

Growing community of inventors

Poitiers, France

Frédéric Becq